Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 12/20 | 0.44 |
| ▸ | CTSS | P25774 | 6/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18866617 | 1.00 | CA1 (0.46) | CA1CA2CA7MEN1GAA | |
| SCHEMBL28981403 | 0.94 | CA1 (0.44) | CA1CA2CA7MEN1GAA | |
| SCHEMBL1000144 | 0.90 | CA1 (0.49) | CA1CA2CA7MEN1GAA | |
| SCHEMBL23833052 | 0.90 | CA1 (0.49) | CA1CA2CA7MEN1GAA | |
| SCHEMBL6375701 | 0.90 | CA1 (0.49) | CA1CA2CA7MEN1GAA | |
| SCHEMBL8270649 | 0.85 | CA1 (0.47) | CA1CA2CA7MEN1GAA | |
| SCHEMBL27490793 | 0.83 | MEN1 (0.45) | CA1CA2CA7MEN1GAA | |
| SCHEMBL12734600 | 0.83 | CTSK (0.61) | CTSKCTSS | |
| SCHEMBL15961701 | 0.83 | CTSK (0.61) | CTSKCTSS | |
| SCHEMBL24687980 | 0.83 | TDP1 (0.50) | CA1CA2CA7MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346852-B2 | Substituted adipic acid amides and uses thereof | BRISTOL-MYERS SCUIBB COMPANY (US) | 2016-05-24 | — | — | US | disclosed |
| US-20130345123-A1 | SUBSTITUTED ADIPIC ACID AMIDES AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-26 | — | — | US | disclosed |
| WO-2012125622-A1 | SUBSTITUTED ADIPIC ACID AMIDES AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-20 | — | — | WO | disclosed |
| WO-1994022494-A1 | RADIOLABELED PLATELET GPIIb/IIIa RECEPTOR ANTAGONISTS AS IMAGING AGENTS FOR THE DIAGNOSIS OF THROMBOEMBOLIC DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-13 | — | — | WO | disclosed |
| EP-0108399-B1 | SUBSTITUTED CARBOXYFLUORESCEINS | ABBOTT LABORATORIES (US) | 1987-09-23 | — | — | EP | disclosed |
| US-4476229-A | QUANTITATIVE ANALYSIS OF LIGANDS IN BIOLOGICAL FLUIDS | ABBOTT LABORATORIES (US) | 1984-10-09 | — | — | US | disclosed |
| EP-0108399-A2 | Substituted carboxyfluoresceins | ABBOTT LABORATORIES (US) | 1984-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345123-A1 | SUBSTITUTED ADIPIC ACID AMIDES AND USES THEREOF | NPY4R, ADIPOR1, NPY1R | CA1 3094/4885CA2 1978/4885CA7 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.